Boston, MA — April 21, 2026 — Dewpoint Therapeutics Inc., a clinical-state biotechnology company pioneering condensate therapeutics, presented new preclinical […]
• First MYC condensate-modulating small molecule advanced to Development Candidate• Demonstrates potent, selective inhibition of MYC-driven transcription via condensate modulation• […]
BOSTON, MA – February 4, 2026 | Dewpoint Therapeutics, Inc., a clinical-stage biotechnology company pioneering condensate-modulating therapeutics, today announced that […]
BOSTON, MA – January 8, 2026 – Dewpoint Therapeutics, Inc., a clinical-stage biotechnology company pioneering condensate-modulating therapeutics, today announced the […]
Boston, MA – January 6, 2026 – Dewpoint Therapeutics announced today the launch of a new research initiative to develop an integrated viral phenomics […]
Boston, MA – November 17, 2025 – Dewpoint Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has […]
Boston, Mass. – October 29, 2025 – Dewpoint Therapeutics, the leader in condensate biology, today announced that the U.S. Food […]
Boston, Mass. – October 21, 2025 – Dewpoint Therapeutics today announced the opening of an Investigational New Drug (IND) application […]
Boston, Massachusetts, October 14, 2025 – Dewpoint Therapeutics Inc. – a clinical stage biotechnology company that transforms condensate biology into […]
Boston, Mass. – 10th September 2025 – Dewpoint Therapeutics, the leading biotechnology company in transforming condensate biology into medicine, today announced […]
